Head-To-Head Comparison: Tilray (TLRY) and Mediwound (MDWD)

Share on StockTwits

Tilray (NASDAQ:TLRY) and Mediwound (NASDAQ:MDWD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Institutional & Insider Ownership

32.1% of Mediwound shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Tilray and Mediwound’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tilray N/A N/A N/A
Mediwound -783.30% -210.90% -33.92%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Tilray and Mediwound, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray 0 2 1 0 2.33
Mediwound 0 0 3 0 3.00

Tilray presently has a consensus target price of $103.50, suggesting a potential downside of 30.21%. Mediwound has a consensus target price of $11.33, suggesting a potential upside of 88.89%. Given Mediwound’s stronger consensus rating and higher possible upside, analysts clearly believe Mediwound is more favorable than Tilray.

Earnings and Valuation

This table compares Tilray and Mediwound’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tilray N/A N/A N/A N/A N/A
Mediwound $2.50 million 64.92 -$22.14 million ($0.62) -9.68

Tilray has higher earnings, but lower revenue than Mediwound.

Summary

Mediwound beats Tilray on 5 of the 8 factors compared between the two stocks.

About Tilray

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.